Pfizer’s post-megamerger cost-cutting record? 51,500 jobs in 7 years

Tracy Staton

In the calm after yesterday's Pfizer-AstraZeneca deal storm, it's time to survey the potential fallout. Pfizer's aggressive strategy for avoiding taxes, totted up by The Wall Street Journal, politely thumped by the Financial Times and skewered by In the Pipeline. Fears for the U.K. science community, articulated by any number of U.K. newspapers.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS